DiaMedica Therapeutics (DMAC) EPS (Basic) (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly EPS (Basic) came in at -$0.19 in Q2 2026, down 4.97% on a YoY basis from -$0.2 in Q2 2025, and down 0.78% quarter-over-quarter from -$0.19 in Q1 2026.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) EPS (Basic) (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported EPS (Basic) for 9 consecutive years, with -$0.19 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) fell 4.97% year-over-year to -$0.19; the trailing twelve-month figure through Jun 2026 stood at -$0.61 (down 1.4% YoY), and the FY2025 full-year result was -$0.6, down 16.69% from the prior year.
- EPS (Basic) eased to -$0.19 in Q2 2026 per DMAC's latest filing, from -$0.19 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.09 in Q4 2025 and bottomed at -$0.2 in Q1 2023.
- Historically, EPS (Basic) has averaged -$0.15 across 5 years, with a median of -$0.14 in 2022.
- The sharpest annual moves came in 2022 and 2023: EPS (Basic) surged 36.17% in 2022, then slumped 50.25% in 2023.
- Over 5 years, EPS (Basic) stood at -$0.14 in 2022, then decreased by 10.71% to -$0.16 in 2023, then surged by 33.69% to -$0.11 in 2024, then climbed by 15.29% to -$0.09 in 2025, then plunged by 111.34% to -$0.19 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.19, -$0.19, and -$0.09 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.94 Bn | 195.95 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.74 Bn | 176.57 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 132.05 Bn | 124.20 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.43 Bn | 74.44 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 61.23 Bn | 56.04 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 53.42 Bn | 48.28 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.77 Bn | 30.47 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | DiaMedica Therapeutics | 345.46 Mn | 345.46 Mn | - | -0.19 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.19 |
| Mar 31, 2026 | -0.19 |
| Dec 31, 2025 | -0.09 |
| Sep 30, 2025 | -0.17 |
| Jun 30, 2025 | -0.18 |
| Mar 31, 2025 | -0.18 |
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.15 |
| Jun 30, 2024 | -0.13 |
| Mar 31, 2024 | -0.14 |
| Dec 31, 2023 | -0.16 |
| Sep 30, 2023 | -0.12 |
| Jun 30, 2023 | -0.16 |
| Mar 31, 2023 | -0.20 |
| Dec 31, 2022 | -0.14 |
| Sep 30, 2022 | -0.12 |
| Jun 30, 2022 | -0.13 |
| Mar 31, 2022 | -0.13 |
| Dec 31, 2021 | -0.16 |
| Sep 30, 2021 | -0.18 |